Author

A. Bartha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:statistical model· 3 Assay:proteomics· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Sanchez· 2 shared B. Gyorffy· 2 shared B. Szeitz· 2 shared D. Fenyo· 2 shared E. Wieslander· 2 shared F. Nogueira· 2 shared G. Domont· 2 shared I. B. Nemeth· 2 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Sanchez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts

L. Szadai, A. Bartha, I. P. Parada, A. Lakatos, D. Pal, A. S. Lengyel, N. P. d. Almeida, A. J. Janosi, F. Nogueira, B. Szeitz, V. Doma, N. Woldmar, J. Guedes, Z. Ujfaludi, Z. G. Pahi, , A. Sanchez

The paper identifies six proteins that predict response to immune checkpoint therapy across three melanoma cohorts and correlate with patient survival.

bioRxiv · May 1, 2024Cancer Biology

Identifying Ferroptosis Inducers, HDAC, and RTK Inhibitor Sensitivity in Melanoma Subtypes through Unbiased Drug Target Prediction

I. Pla, B. L. Szabolcs, P. N. Peter, Z. Ujfaludi, Y. Kim, P. Horvatovich, A. Sanchez, K. Pawlowski, E. Wieslander, J. Guedes, D. M. Pal, A. A. Ascsillan, L. H. Betancourt, I. B. Nemeth, J. Gil, , L. V. Kemeny

This paper identifies potential drug targets and predicts treatment efficacy and resistance in melanoma subtypes using proteogenomic data and drug sensitivity analysis.

bioRxiv · Feb 8, 2024 · PreprintCancer Biology

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors

O. Papp, V. Jordan, S. Hetey, R. Balazs, A. Bartha, N. N. Ordasi, S. Kamp, B. Farkas, J. Mettetal, J. R. Dry, D. Young, D. Veres, B. Sidders, K. C. Bulusu

The paper introduces a network biology-driven simulation method to predict effective drug combinations and identify biomarkers for DNA Damage Response inhibitors using cancer cell avatars.

bioRxiv · Nov 20, 2023Cancer Biology